Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Meetings & Events

Trans-NIH Angiogenesis Workshop; May 20-21, 2013
  • Speaker Biosketches

    Portrait of David Cheresh, PhD

    David Cheresh, PhD
    (University of California, San Diego)


    Dr. David Cheresh studies the mechanism of action of signaling networks that regulate tumor growth, stemness, drug resistance and metastasis. He discovered the avb3 integrin is a functional marker of angiogenic blood vessels. His work is basic and translational focusing on new strategies for biologically-based drug development. In particular, he studies how integrins and growth factor receptors promote, cell survival, angiogenesis and tumor invasion. His work has lead to the development of several drugs now in various stages of clinical development. Cheresh's research in this area has been widely cited with seven of his peer-reviewed publications being cited >1000 times. David Cheresh was the scientific founder of TargeGen a San Diego based Biotechnology Company which developed a number of small molecules based in part on discoveries made in the Cheresh laboratory. TargeGen's JAK2 inhibitor has shown clinical activity in patients with myeloproliferative disease. Sanofi Aventis recently acquired TargeGen and will soon be reporting Phase III data on the TargeGen developed JAK2 inhibitor. Most recently, Cheresh and his colleagues have developed a novel scaffold based chemistry approach to stabilize kinases in their inactive state. These studies have lead to the discovery of a first in class Raf inhibitor that has distinct advantages relative to ATP mimetics of RAF. Cheresh and his colleagues at UCSD have founded a new startup company (Amitech Therapeutic Solutions, ATS) which focuses on the discovery of allosteric inhibitors of kinases such as those targeting Raf and other important molecules/pathways relevant to cancer and inflammatory disease.


    The Cheresh laboratory focuses on how microRNAs influence blood vessel growth in tumors and regulate the “angiogenic switch” enabling tumors to access a blood supply. The lab has also developed a new drug discovery platform that targets tumor-associated kinases by chemically locking them in the inactive state. To this end, a new drug is being developed that allosterically inhibits RAF kinase and has shown strong inhibitory activity against breast cancer, pancreatic cancer and brain cancer in preclinical cancer models. One near term goal of this research effort is to test this drug in patients with late stage cancer at the Moores Cancer Center.

    « Previous  |  Next »



Workshop Organizer: NIH

NCI:Nancy Emenaker, PhD, RD
Suzanne Forry-Schaudies, PhD
NHLBI: Yunling Gao, MD, PhD
NIDDK: Teresa Jones, MD

NIH - National Institutes of Health: Turning Discovery Into Health


Back to top

Trans-NIH Angiogenesis header